News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Millennium: The Takeda Oncology Company Initiates Global TOURMALINE-AL1 Pivotal Phase 3 Trial of MLN9708 In Patients with Relapsed or Refractory Primary (AL) Amyloidosis


10/19/2012 9:00:26 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced the initiation of an international phase 3 clinical trial evaluating once-weekly oral MLN9708 plus dexamethasone in patients with relapsed or refractory light chain AL amyloidosis. The multi-center study with MLN9708, an investigational oral proteasome inhibitor, plans to enroll patients in Europe, North America, Latin America and the Asia-Pacific region.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES